Research News
View articles by month and year
-
Injectable Herceptin Shows Promise
A study suggests that an injectable form of Herceptin works just as well as and is as safe as the standard IV form of Herceptin to treat HER2-positive, early-stage breast cancer before surgery.
-
Afinitor Approved to Treat Advanced-Stage, Hormone-Receptor-Positive Disease
Afinitor has been approved to be used in combination with Aromasin to treat advanced-stage, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women that has already been treated with Femara or Arimidex.
-
Large Review Study Says Avastin Offers Only Modest Benefits for Metastatic Breast Cancer
Results from a new large review study show that Avastin offers only modest benefits for stopping the growth and spread of metastatic breast cancer.
-
Experimental Vaccine May Help Reduce Recurrence Risk of HER2-Positive Disease
A new study has found that an experimental vaccine targeting HER2-positive breast cancer cells lowered the risk of the cancer coming back in women diagnosed with HER2-positive, early-stage breast cancer.
-
Perjeta Improves Overall Survival in HER2-Positive, Metastatic Disease
More results from the CLEOPATRA study show that women who got Perjeta, Herceptin, and Taxotere had better overall survival than women who got only Herceptin and Taxotere.
-
FDA Approves Perjeta for Metastatic, HER2-Positive Disease
The FDA has approved using Perjeta (chemical name: pertuzumab) in combination with Herceptin and Taxotere to treat HER2-positive, metastatic breast cancer that hasn't been treated with either Herceptin or chemotherapy yet.
-
T-DM1 Works Better on Advanced-Stage, HER2-Positive Cancer Than Standard Meds
A study found that women diagnosed with advanced-stage, HER2-positive breast cancer that had stopped responding to a standard regimen lived longer without the cancer growing when they got the experimental medicine T-DM1 compared to women who got a different regimen.
-
Large Review Study Confirms Herceptin’s Benefits
A large review study has found that women diagnosed with HER2-positive breast cancer and treated with Herceptin were less likely to have the cancer come back and more likely to survive compared to women who didn't get Herceptin.
-
Studies Evaluate Treatments Before Surgery for HER2-Positive Disease
Research suggests that using both Herceptin and Tykerb with Taxol before surgery to treat early-stage or locally advanced HER2-positive breast cancer is better than either alone with Taxol; if only one is given before surgery, Herceptin offers more benefits than Tykerb.
-
Afinitor Before Surgery Doesn’t Help Treat HER2-Negative Breast Cancer
Research has found that adding Afinitor to paclitaxel didn't improve the response to neoadjuvant treatment with paclitaxel in women diagnosed with advanced-stage, HER2-negative breast cancer.
